Nevertheless, the monotherapy approach seemed to be not effective in the case of poor immunogenic tumors, thus inducing studies and trials focused on the combination of ipilimumab with other anti-tumor drugs, such as IL-2, peptide vaccine, chemotherapy drug decarbazine [21,22,23], or with other immune checkpoint inhibitors. Here, IL2 is linked to neoplasm.